Allergy and Airway: Asthma IV |

Type 2 Innate Lymphoid Cells: A Novel Biomarker of Eosinophilic Airway Inflammation in Patients With Mild to Moderate Asthma FREE TO VIEW

Liang Dong
Author and Funding Information

Qilu Hospital of Shandong University, Jinan, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A43. doi:10.1016/j.chest.2016.02.045
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Eosinophilic airway inflammation can predict the exacerbation of asthma, and we can improve the management of asthma by monitoring the eosinophilic airway inflammation. Although induced sputum and sputum eosinophil count is the gold standard test for diagnosing eosinophilic asthma, a more accessible and receptive method is needed for clinical practice. Type 2 innate lymphoid cells (ILC2) have recently been proposed to play a crucial role in eosinophilic inflammation and have been identified in peripheral blood from patients with asthma. We sought to identify simple and feasible biomarkers which can predict eosinophilic airway inflammation in asthmatic patients.

METHODS: Sputum was induced for the assessment of eosinophils in 150 asthmatic patients. In parallel, the proportion of ILC2s of peripheral blood lymphocytes (%ILC2), blood eosinophil counts, total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO) and lung function tests were measured.

RESULTS: 126 patients finished sputum induction and produced adequate sputum. The ILC2 level was significantly increased in eosinophilic asthmatic patients compared with non-eosinophilic asthmatic patients (0.117±0.090versus0.035±0.021, p<0.001). A multiple regression model, including age, sex, BMI, blood eosinophil counts, FeNO, IgE and %ILC2, showed that %ILC2, blood eosinophil counts and FeNO were correlative factors of sputum eosinophil counts (p<0.001, p=0.037, p<0.001, respectively) and %ILC2 was the most significant subset of airway eosinophilic inflammation (Estimate=11.385). A receiver operating characteristic (ROC) analysis showed a sensitivity of 67.7% and a specificity of 95.3% for %ILC2 of 0.076 to distinguish eosinophilic asthmatic patients from non-eosinophilic asthmatic patients.

CONCLUSIONS: ILC2 is a surrogate marker of airway eosinophilic inflammation in patients with mild to moderate asthma and has great potential advantages for selecting the asthmatic patients most likely to benefit from therapeutics targeting Th2 inflammation.

CLINICAL IMPLICATIONS: Our study demonstrates that blood ILC2 can reflect airway eosinophilic inflammation in mild to moderate asthmatic patients, and this provides a new insight for the biomarker of eosinophilic asthma. The level of ILC2 might help identify and select those patients most likely to respond to these biological therapeutics.

DISCLOSURE: The following authors have nothing to disclose: Liang Dong

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543